MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1182/bloodadvances.2023010335

Медицинская библиотека · Blood advances · 2024

Class II ferroptosis inducers are a novel therapeutic approach for t(4;14)-positive multiple myeloma.

Zhang Jiasi, Liu Yuxi, Zuo Liping, Fan Fengjuan, Yan Han, Zhao Fei, Li Junying, Ma Chi, Li Qun, Xu Aoshuang, Xu Jian, Zhang Bo, Hu Yu, Sun Chunyan

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

Multiple myeloma (MM) is a clonal plasma cell malignancy that is characterized by genetic heterogeneity. The cytogenetic abnormality t(4;14) strongly predicts poor outcome in patients with MM, even in the era of novel drugs. Ferroptosis is a new approach to antitumor therapy, but the relationship between ferroptosis and MM cytogenetic abnormalities remains largely unclear. In this study, we show that t(4;14)-positive but not t(4;14)-negative MM cells are susceptible to class II ferroptosis inducers (FINs) in a preclinical setting, which is dependent on the significant upregulation of the MM SET domain-containing protein (MMSET). Mechanistically, MMSET upregulates acyl-coenzyme A synthetase long-chain family member 4 transcription by binding to its promoter region, leading to increased polyunsaturated fatty acid (PUFA) levels and enhanced sensitivity of t(4;14)-positive MM cells to ferroptosis. Supplementation with PUFAs efficiently restores the susceptibility of t(4;14)-negative MM cells to ferroptosis. In addition, combining class II FIN treatment with bortezomib in t(4;14)-positive MM cells attenuates cellular glutathione and induces both apoptosis and ferroptosis levels by inhibiting the increase in solute carrier family 7 member 11, demonstrating synergistic antitumor activity in vitro and in a xenograft model. Taken together, our findings suggest that targeting ferroptosis with class II FINs is a novel and promising therapeutic approach to improve the outcome of t(4;14)-positive patients with MM.

Для цитирования: Zhang Jiasi, Liu Yuxi, Zuo Liping, Fan Fengjuan, Yan Han, Zhao Fei, Li Junying, Ma Chi, Li Qun, Xu Aoshuang, Xu Jian, Zhang Bo, Hu Yu, Sun Chunyan. Class II ferroptosis inducers are a novel therapeutic approach for t(4;14)-positive multiple myeloma.. Blood advances. 2024. DOI: 10.1182/bloodadvances.2023010335.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.